NVTA - NVTA インビティ ()

NVTAのニュース

   Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)  2021/01/14 12:30:00 PR Newswire
SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Janssen Research & Development, LLC (Janssen), Novartis and Genentech, a member of the Roche Group, to…
   Concert Genetics Launches Preferred Laboratory Network  2021/01/12 14:03:00 PR Newswire
NASHVILLE, Tenn., Jan. 12, 2021 /PRNewswire/ -- As part of its ongoing commitment to advance transparency and efficiency in precision medicine, Concert Genetics today announced the launch of a preferred network of genetic testing laboratories. Invitae, PreventionGenetics, and GeneDx Inc.,…
   Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume  2021/01/11 12:30:00 PR Newswire
SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2020 results, reporting strong growth in volume and revenue, signaling continued momentum into 2021. "We are very pleased by the…
   Insider Selling: Invitae Co. (NYSE:NVTA) Insider Sells $3,400,841.08 in Stock  2020/12/24 09:40:41 Watchlist News
Invitae Co. (NYSE:NVTA) insider Jason W. Myers sold 71,869 shares of Invitae stock in a transaction dated Wednesday, December 16th. The stock was sold at an average price of $47.32, for a total value of $3,400,841.08. Following the sale, the insider now owns 1,211,099 shares in the company, valued at approximately $57,309,204.68. The transaction was […]
   Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster  2020/12/17 12:30:00 PR Newswire
SAN FRANCISCO, Dec. 17, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced all patients who undergo exome testing with Invitae will receive routine case-level reanalysis of their findings every six months for at least three years. Reanalysis…
   Insider Selling: Invitae Co. (NYSE:NVTA) Insider Sells $3,400,841.08 in Stock  2020/12/24 09:40:41 Watchlist News
Invitae Co. (NYSE:NVTA) insider Jason W. Myers sold 71,869 shares of Invitae stock in a transaction dated Wednesday, December 16th. The stock was sold at an average price of $47.32, for a total value of $3,400,841.08. Following the sale, the insider now owns 1,211,099 shares in the company, valued at approximately $57,309,204.68. The transaction was […]
   Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster  2020/12/17 12:30:00 PR Newswire
SAN FRANCISCO, Dec. 17, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced all patients who undergo exome testing with Invitae will receive routine case-level reanalysis of their findings every six months for at least three years. Reanalysis…
   [FREE SLIDE DECK] Key Players in Genetic Testing  2020/12/02 22:01:00 Business Insider
Summary List Placement The human genome was sequenced – or read in its entirety – for the first time in 2003, after more than 20 years of work. In the ensuing decades, genetic information catapulted into mainstream healthcare driven largely by the rapid decline in cost for DNA sequencing technology. Today, there is a massive opportunity for genetic testing firms to help healthcare organizations use DNA to steer more personalized treatments. In the Key Players in Genetic Testing report, Insider Intelligence gives an overview of the four genetic testing companies – 23andMe, Ancestry, Color, and Invitae – that are racing to the forefront of healthcare. This exclusive report can be yours for FREE today. Join the conversation about this story »
   PARP Inhibitor Biomarkers Market - Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc.  2020/11/24 12:31:12 OpenPR
An informative study on the PARP Inhibitor Biomarkers Market from 2020-2027 has lately released for the database of Coherent Market Insights that helps by making business conclusions and shape the future of the organizations. Individual analysis of top regions and
   Direct-to-consumer Genetic Testing Market Share and SWOT Analysis: Myriad Genetics Inc., 23andMe Inc., Invitae, Ambry Genetics  2020/11/16 14:09:16 OpenPR
The Direct-to-consumer Genetic Testing market report gives an in-depth analysis of the global market where it includes drivers, restraints, and trends, and opportunities contributing in the growth of the market. The Direct-to-consumer Genetic Testing report also consists of geographical analysis
   Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster  2020/12/17 12:30:00 PR Newswire
SAN FRANCISCO, Dec. 17, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced all patients who undergo exome testing with Invitae will receive routine case-level reanalysis of their findings every six months for at least three years. Reanalysis…
   [FREE SLIDE DECK] Key Players in Genetic Testing  2020/12/02 22:01:00 Business Insider
Summary List Placement The human genome was sequenced – or read in its entirety – for the first time in 2003, after more than 20 years of work. In the ensuing decades, genetic information catapulted into mainstream healthcare driven largely by the rapid decline in cost for DNA sequencing technology. Today, there is a massive opportunity for genetic testing firms to help healthcare organizations use DNA to steer more personalized treatments. In the Key Players in Genetic Testing report, Insider Intelligence gives an overview of the four genetic testing companies – 23andMe, Ancestry, Color, and Invitae – that are racing to the forefront of healthcare. This exclusive report can be yours for FREE today. Join the conversation about this story »
   PARP Inhibitor Biomarkers Market - Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc.  2020/11/24 12:31:12 OpenPR
An informative study on the PARP Inhibitor Biomarkers Market from 2020-2027 has lately released for the database of Coherent Market Insights that helps by making business conclusions and shape the future of the organizations. Individual analysis of top regions and
   Direct-to-consumer Genetic Testing Market Share and SWOT Analysis: Myriad Genetics Inc., 23andMe Inc., Invitae, Ambry Genetics  2020/11/16 14:09:16 OpenPR
The Direct-to-consumer Genetic Testing market report gives an in-depth analysis of the global market where it includes drivers, restraints, and trends, and opportunities contributing in the growth of the market. The Direct-to-consumer Genetic Testing report also consists of geographical analysis
   Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020  2020/11/05 21:05:00 PR Newswire
/PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter…

calendar